Page last updated: 2024-10-29

avapro and Stroke

avapro has been researched along with Stroke in 21 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke."9.16A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."9.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."9.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation."8.86Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? ( Lane, DA; Lip, GY, 2010)
"Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198."7.72Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004)
"Stroke is a major cause of mortality and disability worldwide."6.49Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013)
"Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction."5.20Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015)
"To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke."5.16A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012)
" In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5."5.14Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."5.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."5.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation."4.86Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? ( Lane, DA; Lip, GY, 2010)
"Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension."3.79Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013)
"Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198."3.72Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004)
"To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)."3.71Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002)
"Stroke is a major cause of mortality and disability worldwide."2.49Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (28.57)29.6817
2010's15 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Culman, J1
Jacob, T1
Schuster, SO1
Brolund-Spaether, K1
Brolund, L1
Cascorbi, I1
Zhao, Y1
Gohlke, P1
Antoniou, T1
Camacho, X1
Yao, Z1
Gomes, T1
Juurlink, DN1
Mamdani, MM1
Kikuchi, K1
Tancharoen, S1
Ito, T1
Morimoto-Yamashita, Y1
Miura, N1
Kawahara, K1
Maruyama, I1
Murai, Y1
Tanaka, E1
Hasegawa, Y1
Nakagawa, T1
Uekawa, K1
Ma, M1
Lin, B1
Kusaka, H1
Katayama, T1
Sueta, D1
Toyama, K1
Koibuchi, N1
Kim-Mitsuyama, S1
Sandhu, RK1
Hohnloser, SH3
Pfeffer, MA3
Yuan, F1
Hart, RG4
Yusuf, S5
Connolly, SJ4
McAlister, FA1
Healey, JS3
Tan, CH1
Tang, SC1
Lin, RJ1
Jeng, JS1
Lip, GY1
Lane, DA1
De Caterina, R2
Pogue, J4
Chrolavicius, S3
Budaj, A1
Morais, J1
Renda, G1
Tebbe, U1
Bramlage, P1
Lüders, S1
Cuneo, A1
Sistig, P1
de Haan, F1
Schmieder, R1
Böhm, M1
Paar, WD1
Schrader, J1
Flather, M1
Joyner, CD1
Holtkamp, FA1
de Zeeuw, D1
de Graeff, PA1
Laverman, GD1
Berl, T1
Remuzzi, G1
Packham, D1
Lewis, JB1
Parving, HH1
Lambers Heerspink, HJ1
Khan, M2
Kamal, AK2
Beer, C1
Blacker, D1
Bynevelt, M1
Hankey, GJ1
Puddey, IB1
Karpov, IuA1
Shimamura, T1
Masui, M1
Torii, M1
Nakajima, M1
Graham, D2
Hamilton, C1
Beattie, E1
Spiers, A1
Dominiczak, AF2
Connolly, S1
Hart, R1
Pfeffer, M2
Hohnloser, S2
Flaker, G1
Brosnan, MJ1
Hamilton, CA1
Lygate, CA1
Jardine, E1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249795]Phase 39,016 participants (Actual)Interventional2003-06-30Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178]Phase 36,706 participants (Actual)Interventional2003-07-31Terminated
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948]1,080 participants (Anticipated)Observational [Patient Registry]2018-02-09Active, not recruiting
Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944]Phase 4400 participants (Anticipated)Interventional2015-10-13Completed
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death From Any Cause

The considered event is the death over the duration of the follow-up whatever the cause, cardiovascular or non-cardiovascular. (NCT00249795)
Timeframe: Median follow-up of 4.5 years

Interventionparticipants (Number)
Irbesartan949
Placebo929

First Hospitalisation for Heart Failure (HF)

The considered event is the first overnight hospital stay for HF over the duration of the follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years

Interventionparticipants (Number)
Irbesartan482
Placebo551

First Hospitalisation for Other Cardiovascular (CV) Cause

The considered event is the overnight hospital stay for any CV cause other than Heart Failure over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years

Interventionparticipants (Number)
Irbesartan1186
Placebo1174

First Occurrence of Any Heart Failure (HF) Episode

The considered event is the first occurence of any HF episode defined as evidence of signs and symptoms of HF with or without hospitalization over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years

Interventionparticipants (Number)
Irbesartan699
Placebo767

First Occurrence of Stroke

The considered event is the first occurrence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) over the duration of follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years

Interventionparticipants (Number)
Irbesartan379
Placebo411

First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication

The first co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal) or vascular death - after validation by the Event Adjudication Committee (EAC). (NCT00249795)
Timeframe: Median follow-up of 4.5 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Vascular death
Irbesartan963136367460
Placebo963123407433

First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke, Vascular Death or Hospitalization for Heart Failure as Per Adjudication

The second co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal), vascular death or hospitalization for heart failure - after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Vascular death- Hospitalization for heart failure
Irbesartan1236122340331443
Placebo1291112375291513

Reviews

4 reviews available for avapro and Stroke

ArticleYear
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
    International journal of molecular sciences, 2013, Sep-13, Volume: 14, Issue:9

    Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou

2013
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
    The American journal of medicine, 2010, Volume: 123, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Biphenyl Compounds; D

2010
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
    European heart journal, 2011, Volume: 32, Issue:12

    Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure;

2011
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
    Kardiologiia, 2002, Volume: 42, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor

2002

Trials

6 trials available for avapro and Stroke

ArticleYear
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid

2015
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt

2010
Irbesartan in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-10, Volume: 364, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biphenyl Compounds; Blood Pressu

2011
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    International journal of stroke : official journal of the International Stroke Society, 2012, Volume: 7, Issue:2

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds;

2012
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny

2008

Other Studies

11 other studies available for avapro and Stroke

ArticleYear
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
    Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl

2017
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Sep-03, Volume: 185, Issue:12

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo

2013
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
    Translational stroke research, 2016, Volume: 7, Issue:1

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Bl

2016
Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker.
    Journal of neurology, neurosurgery, and psychiatry, 2010, Volume: 81, Issue:10

    Topics: Aged, 80 and over; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female;

2010
Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.
    Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:12

    Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Card

2010
Atrial fibrillation, is warfarin the only option for stroke prevention?
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cl

2011
Atrial fibrillation, is warfarin the only option for stroke prevention?
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
    International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2004, Volume: 26, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Comp

2004
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
    Journal of hypertension, 2004, Volume: 22, Issue:2

    Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba

2004
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
    Journal of hypertension, 2002, Volume: 20, Issue:2

    Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort

2002